Advances in Cardiovascular Imaging Imaging Phenotype versus Genotype in Hypertrophic Cardiomyopathy State-of-the Art in Genetics of Hcm Sarcomere and Z-disc Protein Gene Mutations State-of-the-art in Imaging in Hcm Assessment of Morphology

H ypertrophic cardiomyopathy (HCM) is a common monogenetic cardiac disease with a prevalence of 0.2% 1 that usually is inherited as an autosomal dominant trait with variable penetrance and expression. Clinically, HCM is defined by the presence of left ventricular (LV) hypertrophy (LVH) unexplained by abnormal loading conditions. 1 The natural history varies from an asymptomatic course to drug-refractory angina/dyspnea, sudden cardiac death (SCD), and end-stage heart failure. The incidence of HCM-related SCD is approximately 1% to 2% in children and adolescents and 0.5% to 1% in adults. 2,3 In this review, we examine the impact of advanced diagnostic imaging technologies on HCM, with particular emphasis on the detection of particular genetic subtypes. In Ϸ60% of cases, HCM is inherited as an autosomal dominant trait caused by mutations in genes coding for cardiac sarcomere proteins (Figure 1). 4 –7 Mutations in genes encoding Z-disc proteins and proteins involved in calcium regulation account for Ͻ5% of cases. The absence of sarco-meric gene mutations can be explained by limitations of current mutation detection techniques or mutations in as yet unidentified genes, but in some cases, hypertrophy is caused by other diseases that mimic the phenotype of sarcomeric protein disease. Table 1 lists genetic disorders associated with HCM. More than 600 different sarcomeric gene mutations are reported in patients with HCM. 8 –16 The majority are missense mutations, but nonsense, frameshift, and in-frame insertion/ deletion mutations also occur. Most mutations are characterized by incomplete penetrance and variable clinical expression likely due to locus heterogeneity and the effect of mutations at different locations within the same gene. Most mutations probably have a dominant negative effect on sarcomere function, but in some cases, haploinsufficiency (ie, only a single functional copy of a gene, the other being inactivated by the mutation) also may be important. It is suggested that hypertrophy results from reduced contractile function, but studies of myocyte function in patients with mutations in sarcomere protein genes are contradictory. Nevertheless, murine models of sarcomeric mutations show increased calcium sensitivity and altered calcium cycling between sarcomere and sarcoplasmic reticu-lum. In vitro studies using purified myosin filaments and skinned papillary muscle have reported increased calcium sensitivity of force development that results in impaired ventricular relaxation in vivo. 17,18 Z-discs are lateral boundaries of the sarcomere that play a fundamental role in mechanical stretch sensing. Several mutations in genes coding for Z-disc proteins have been implicated in HCM, …

[1]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[2]  A. Keren,et al.  Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2010, European heart journal.

[3]  Deborah H. Kwon,et al.  Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. , 2010, The Journal of thoracic and cardiovascular surgery.

[4]  M. Desai,et al.  Aortic stiffness independently predicts exercise capacity in hypertrophic cardiomyopathy: a multimodality imaging study , 2010, Heart.

[5]  A. Tajik,et al.  Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[6]  Raffaele Izzo,et al.  Melusin gene (ITGB1BP2) nucleotide variations study in hypertensive and cardiopathic patients , 2009, BMC Medical Genetics.

[7]  M. Desai,et al.  Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. , 2009, JACC. Cardiovascular imaging.

[8]  M. Desai,et al.  Aortic stiffness is increased in hypertrophic cardiomyopathy with myocardial fibrosis: novel insights in vascular function from magnetic resonance imaging. , 2009, Journal of the American College of Cardiology.

[9]  J. Towbin,et al.  Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[10]  N. Smedira,et al.  Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. , 2009, Journal of the American College of Cardiology.

[11]  N. Smedira,et al.  Steep left ventricle to aortic root angle and hypertrophic obstructive cardiomyopathy: study of a novel association using three-dimensional multimodality imaging , 2009, Heart.

[12]  W. Manning,et al.  Response to Letter Regarding Article, “Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy” , 2009 .

[13]  K. Rauen,et al.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. , 2009, Current opinion in genetics & development.

[14]  Scott D Flamm,et al.  Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[15]  Luigi Rega,et al.  Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[16]  C. Rochitte,et al.  Value of Real Time Three‐Dimensional Echocardiography in Patients with Hypertrophic Cardiomyopathy: Comparison with Two‐Dimensional Echocardiography and Magnetic Resonance Imaging , 2008, Echocardiography.

[17]  N. Smedira,et al.  Diagnostic value of left ventricular outflow area in patients with hypertrophic cardiomyopathy: a real-time three-dimensional echocardiographic study. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[18]  Rachael,et al.  Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. , 2008, Mayo Clinic proceedings.

[19]  W. Manning,et al.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[20]  W. Manning,et al.  Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[21]  Mario J. Garcia,et al.  Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study , 2008, The International Journal of Cardiovascular Imaging.

[22]  S. Ommen,et al.  Evaluation of Left Ventricular Filling Pressures by Doppler Echocardiography in Patients With Hypertrophic Cardiomyopathy: Correlation With Direct Left Atrial Pressure Measurement at Cardiac Catheterization , 2007, Circulation.

[23]  S. Ommen,et al.  Abstract 539: Molecular and Functional Characterization of Novel Hypertrophic Cardiomyopathy Susceptibility Mutations in TNNC1-Encoded Troponin C , 2007 .

[24]  Mario J. Garcia,et al.  Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy , 2007, Heart.

[25]  M. Robson,et al.  Evidence for Microvascular Dysfunction in Hypertrophic Cardiomyopathy: New Insights From Multiparametric Magnetic Resonance Imaging , 2007, Circulation.

[26]  J. Zamorano,et al.  Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. , 2007, European heart journal.

[27]  A. Tajik,et al.  Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[28]  Michael J Ackerman,et al.  Echocardiographic-determined septal morphology in Z-disc hypertrophic cardiomyopathy. , 2006, Biochemical and biophysical research communications.

[29]  Michael J Ackerman,et al.  Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. , 2006, Mayo Clinic proceedings.

[30]  Lynn Weinert,et al.  Use of real-time 3-dimensional transthoracic echocardiography in the evaluation of mitral valve disease. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[31]  W. Mckenna,et al.  Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy , 2005, Heart.

[32]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[33]  Michael Jerosch-Herold,et al.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy , 2005, Circulation.

[34]  R. Kim,et al.  Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. , 2005, European heart journal.

[35]  T. Kato,et al.  Discrimination of Nonobstructive Hypertrophic Cardiomyopathy From Hypertensive Left Ventricular Hypertrophy on the Basis of Strain Rate Imaging by Tissue Doppler Ultrasonography , 2004, Circulation.

[36]  A. Tajik,et al.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[37]  P. Dimitrow,et al.  Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. , 2004, Magnetic Resonance Imaging.

[38]  C. Asher,et al.  Safety of stress testing in patients with hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[39]  D. Pennell,et al.  Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography , 2004, Heart.

[40]  J. Towbin,et al.  Characterization of Left Ventricular Diastolic Function by Tissue Doppler Imaging and Clinical Status in Children With Hypertrophic Cardiomyopathy , 2004, Circulation.

[41]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[42]  I. Olivotto,et al.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[43]  Daniel B Ennis,et al.  Assessment of regional systolic and diastolic dysfunction in familial hypertrophic cardiomyopathy using MR tagging , 2003, Magnetic resonance in medicine.

[44]  M. Quiñones,et al.  Tissue Doppler Imaging Predicts the Development of Hypertrophic Cardiomyopathy in Subjects With Subclinical Disease , 2003, Circulation.

[45]  S. Dimauro,et al.  Mitochondrial respiratory-chain diseases. , 2003, The New England journal of medicine.

[46]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[47]  Mario J. Garcia,et al.  Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. , 2003, The American journal of cardiology.

[48]  F. T. ten Cate,et al.  Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. , 2003, Journal of the American College of Cardiology.

[49]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[50]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[51]  A. Tajik,et al.  Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. , 2002, The American journal of cardiology.

[52]  S. Solomon,et al.  Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy , 2002, Circulation.

[53]  B. Maron Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[54]  J. Seidman,et al.  Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. , 2002, The Journal of clinical investigation.

[55]  J. Plana,et al.  Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. , 2001, The American journal of cardiology.

[56]  M. Quiñones,et al.  Tissue Doppler Imaging Consistently Detects Myocardial Abnormalities in Patients With Hypertrophic Cardiomyopathy and Provides a Novel Means for an Early Diagnosis Before and Independently of Hypertrophy , 2001, Circulation.

[57]  H. Watkins,et al.  Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. , 2001, Human molecular genetics.

[58]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[59]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[60]  D. Szczesna,et al.  Abnormal Contractile Function in Transgenic Mice Expressing a Familial Hypertrophic Cardiomyopathy-linked Troponin T (I79N) Mutation* , 2001, The Journal of Biological Chemistry.

[61]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[62]  J. Seidman,et al.  Homozygous Mutation in Cardiac Troponin T: Implications for Hypertrophic Cardiomyopathy , 2000, Circulation.

[63]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[64]  T. Magnuson,et al.  Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis , 2000, Nature Genetics.

[65]  M. Quiñones,et al.  Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[66]  J. Seidman,et al.  Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. , 1999, Circulation research.

[67]  M. Quiñones,et al.  Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. , 1999, Circulation.

[68]  E. Schwammenthal,et al.  Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility. , 1998, Circulation.

[69]  M. Verani,et al.  Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[70]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[71]  A. Marian,et al.  Molecular Genetic Basis of Hypertrophic Cardiomyopathy: , 1998, Journal of cardiovascular electrophysiology.

[72]  M. Matsuzaki,et al.  Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.

[73]  H. Watkins,et al.  Sudden death due to troponin T mutations. , 1997, Journal of the American College of Cardiology.

[74]  A J Tajik,et al.  Noninvasive doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. , 1996, Journal of the American College of Cardiology.

[75]  I. Rayment,et al.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle , 1996, Nature Genetics.

[76]  J. Seidman,et al.  Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[77]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[78]  M. Burch,et al.  Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.

[79]  M. Proschan,et al.  Morphology of the "athlete's heart" assessed by echocardiography in 947 elite athletes representing 27 sports. , 1994, The American journal of cardiology.

[80]  L. Axel,et al.  Regional Heterogeneity of Function in Hypertrophic Cardiomyopathy , 1994, Circulation.

[81]  Christine E. Seidman,et al.  α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.

[82]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[83]  J. Seidman,et al.  A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.

[84]  S. Solomon,et al.  Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. , 1989, The New England journal of medicine.

[85]  B. Healy,et al.  Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. , 1989, Circulation.

[86]  W. Williams,et al.  Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. , 1985, Progress in cardiovascular diseases.

[87]  D. Judge,et al.  Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. , 2018, Journal of cardiac failure.

[88]  B. Maron,et al.  Hypertrophic Cardiomyopathy Prognostic Value of Systemic Blood Pressure Response During Exercise in a Community-Based Patient Population With Hypertrophic Cardiomyopathy , 2016 .

[89]  M. Cheitlin,et al.  Myocardial Scar Visualized by Cardiovascular Magnetic Resonance Imaging Predicts Major Adverse Events in Patients With Hypertrophic Cardiomyopathy , 2011 .

[90]  N. Smedira,et al.  Abnormally thickened papillary muscle resulting in dynamic left ventricular outflow tract obstruction: an unusual presentation of hypertrophic cardiomyopathy. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[91]  O. Kamp,et al.  Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy , 2007, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[92]  M. Sheppard,et al.  The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[93]  W. Kindermann,et al.  [Left ventricular mass in endurance-athletes with athlete's heart and untrained subjects--comparison between different echocardiographic methods and MRI]. , 2003, Zeitschrift fur Kardiologie.

[94]  O. Simonetti,et al.  An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.

[95]  S. Nagueh,et al.  Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[96]  A. Børglum,et al.  Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.